

**IN THE SPECIFICATION:**

Amend the specification as follows:

On page 3, line 9, after “day”, insert -- . --, and delete “therefore” and insert therefor

-- Therefore --.

On page 3, line 21, delete “differencies” and insert therefor -- differences --.

On page 4, line 27, delete “Un-inhibited” and insert therefor -- Uninhibited --.

On page 4, line 30, delete “un-inhibited” and insert therefor -- uninhibited --.

On page 9, line 19, delete “WO 95/01783” and insert therefor -- U.S. Patent No. 5,690,960 --.

On page 9, line 20, delete “WO 96/01623” and insert therefor -- U.S. Patent No. 5,817,338 --.

On page 9, lines 21 and 22, delete “WO 95/01783 and WO 96/01623, hereby incorporated in

whole by references” and insert therefor -- U.S. Patent No. 5,690,960 and U.S. Patent No.

5,817,338, herein incorporated by reference in their entirety --.

**IN THE CLAIMS:**

Cancel claims 12-14 and 17 without prejudice.

Amend claims 1-11, 15 and 16 as follows:

1. (Amended) An administration regimen for improved inhibiton of gastric acid secretion characterized by [giving] an extended blood plasma profile of an [a] H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor, comprising the oral administration of a pharmaceutical formulation comprising a therapeutically effective amount of [characterized in that] the H<sup>+</sup>, K<sup>+</sup>-ATPase inhibitor having [is a compound with] the formula I